



OPTIGEN[®] LLC

for the genetic advantage

Test Report

JACQUELYN C CARY
20155 ARROWHEAD STREET NW
CEDAR, MN 55011
USA

Optigen Accession #: **12-7437**
Report issued for: **CALLIE**

OptiGen Test Certificate

Optigen Accession #: **12-7437**

Test Completed: **09/14/2012**
Report Issued: **09/17/2012**

Test Performed: **CEA/CH test**

Result: **Carrier**
Sample Type: **Swab**

Registered Name: **ROYALTY'S PRINCESS CALLIDORA**

Reg#: **DN28261903**

Breed: **Collie**


ID#: **076-780-308**

Sex: **Female**

Date of Birth: **July 12, 2010**

Owner(s):

JACQUELYN C CARY



Susan Peasartelling
OptiGen Authorized Signature

www.optigen.com

Test Results: Genotype of your dog is **CARRIER**.

Risk for developing Collie Eye Anomaly/Choroidal Hypoplasia (CEA/CH): This dog will never develop CEA/CH.

Significance for breeding: This dog should only be bred to a mate of normal CEA/CH genotype in order to avoid producing pups affected with CEA/CH.

This interpretation is based on the test result of the DNA test for the specific mutation identified as causing CEA/CH in Collies as of the date on this report.

For further information, please consult the OptiGen website at www.optigen.com.

Note: The use of this test is patent protected and licensed to OptiGen. See http://www.optigen.com/opt9_patent.html for details.

International DNA Based Genetic Database: To register this result with OFA, make a copy, sign below, mail WITH FEE, to OFA, 2300 E. Nifong Blvd, Columbia, MO 65201-3856 or FAX to 573-875-5073. www.offa.org

I hereby certify that the sample submitted was of the animal described on this application. I authorize the OFA to release all information on the test results thus placing the results in the public domain and I hereby release OFA from any and all liability associated with the release of test information.

Signature of owner or authorized representative: _____

Cornell Business & Technology Park

tel: 607.257.0301

fax: 607.257.0353

767 Warren Road, Suite 300, Ithaca, NY 14850

email: genetest@optigen.com

web: www.optigen.com